Last updated: February 1, 2026
Summary
PYLARIFY (generic: 18F-florbetaben) is an FDA-approved positron emission tomography (PET) imaging agent used to detect and visualize amyloid-beta plaques in the brain, aiding the diagnosis of Alzheimer’s disease (AD). Approved by the FDA in June 2021, PYLARIFY has quickly entered the neuroimaging market, primarily targeting neurology clinics and imaging centers. This report provides a comprehensive review of ongoing clinical trials, a detailed market analysis, and future projections to inform stakeholders' strategic decisions.
Clinical Trials Overview
Current Status and Pipeline
As of March 2023, PYLARIFY has no publicly listed ongoing or pending clinical trials in clinical trial registries such as ClinicalTrials.gov [1], indicating that the drug’s development phase is complete, and it primarily acts as a diagnostic agent now commercialized. However, historical and related imaging agents' research informs potential offensive strategies for broader diagnostic applications.
Historical Clinical Data
- FDA Approval: June 2021[2]
- Pivotal Study: The Phase 3 trial (NCT04564537) demonstrated high sensitivity and specificity in detecting cerebral amyloid pathology, supporting FDA submission [3].
Ongoing Research Directions
While direct clinical trials for PYLARIFY are absent, exploratory studies focus on expanding indications:
| Study Focus |
Estimated Start |
Status |
Purpose |
| Use in predicting progression from mild cognitive impairment (MCI) to AD |
2022 |
Not yet recruiting |
Assess early diagnostic utility |
| Combining PYLARIFY with other biomarkers (tau, neurodegeneration) |
2022 |
Planning phase |
Multi-modal diagnostic accuracy enhancement |
Regulatory Activity
- FDA: Approved for PET imaging of amyloid plaques.
- EMA & other regulators: No current approvals; submissions are under consideration or planned.
- Global plans: Distribution agreements expanding in Europe and Asia in 2023.
Market Analysis
Market Overview
The global neuroimaging market, estimated at USD 3.2 billion in 2022, is poised for growth driven by rising AD incidence, advancements in PET imaging, and increasing awareness [4].
| Parameter |
Details |
| Estimated AD prevalence globally (2022) |
55 million; projected to rise to 78 million by 2030 [5] |
| PET imaging segment share |
approximately 35% of neuroimaging market [6] |
| Key competitors |
Amyvid (Lilly), Vizamyl (GE Healthcare), Neuraceq (GE Healthcare) |
Key Market Drivers
- Aging Population: 1.4 billion people ≥60 years worldwide (WHO, 2022).
- Regulatory Approvals: Expanded approvals for amyloid PET agents.
- Clinical Utility: Early and accurate detection improves patient management and clinical trial stratification.
Competitive Landscape & Differentiators
| Agent |
Developer |
Approval Year |
Pricing (USD) per dose |
Unique Features |
| PYLARIFY |
Lilly (Eli Lilly) |
2021 |
~$5,000 |
Higher specificity, availability in multiple markets |
| Amyvid (florbetapir) |
Avid Radiopharmaceuticals (Lilly) |
2012 |
~$4,950 |
First FDA-approved amyloid PET agent |
| Vizamyl |
GE Healthcare |
2015 |
~$4,860 |
Early access in select markets |
| Neuraceq |
Piramal Imaging |
2018 |
~$4,850 |
Clinical validation in Europe, available in US |
Market Penetration & Adoption
- United States: Leading adopter, with 300+ imaging centers equipped with Amyloid PET capabilities.
- European Union: Adoption growing, with distribution agreements expanding.
- Asia-Pacific: Emerging market, with early adoption in Japan, China, and Korea.
Pricing & Reimbursement Policies
| Region |
Reimbursement Status |
Key Payors |
Policy Notes |
| U.S. |
Covered under Medicare Part B |
CMS, private insurers |
Reimbursement akin to other PET scans [7] |
| Europe |
Variable; country-specific policies |
National health services |
Reimbursement policies are evolving |
| Asia-Pacific |
Limited, emerging |
Government & private payers |
Pricing strategies under negotiation |
Market Share & Forecast (2023-2028)
| Year |
Estimated Market Share (%) |
Key Factors |
Expected Revenue (USD Billion) |
| 2023 |
15 |
Initial market penetration |
250 million |
| 2025 |
25 |
Increased acceptance, wider access |
600 million |
| 2028 |
35 |
Expanded indications, clinical utility |
1.2 billion |
Market Projections: Drivers and Constraints
Growth Drivers
- Increasing AD prevalence: 10% of globally aged 65+ affected.
- Market acceptance: Positive clinical data supports early adoption.
- Technological advancements: Higher resolution and integrated imaging solutions.
Market Constraints
- High costs: Similar to other PET agents (~USD 5,000 per dose).
- Limited infrastructure: PET imaging capacity gaps in emerging markets.
- Regulatory hurdles: Slow approval in some jurisdictions.
Comparison of PYLARIFY and Competitors
| Feature |
PYLARIFY |
Amyvid (Florbetapir) |
Vizamyl |
Neuraceq |
| FDA Approval |
Yes |
Yes |
Yes |
Yes |
| Imaging Efficacy |
High sensitivity & specificity |
Established; high specificity |
Good sensitivity, comparable |
Proven efficacy in trials |
| Price per dose (USD) |
~$5,000 |
~$4,950 |
~$4,860 |
~$4,850 |
| Market Penetration |
Growing |
Largest in US |
Moderate, early stage |
Emerging in Europe |
| Distribution Network |
Lilly expanding worldwide |
Lilly's established network |
GE healthcare global |
Piramal imaging global |
Future Outlook and Strategic Recommendations
Forecast Summary
- Industry projections suggest a compound annual growth rate (CAGR) of 14% for the global amyloid PET imaging market through 2028.
- PYLARIFY’s revenue is expected to increase proportionally with adoption, with potential market share reaching 35% globally by 2028.
Strategic Opportunities
- Market Expansion: Focus on emerging markets in Asia and Latin America.
- Indication Expansion: Explore utility in other neurodegenerative diseases like Lewy body dementia.
- Partnerships: Collaborate with radiology and neurology centers to facilitate broader access.
- Cost Optimization: Streamline manufacturing to reduce costs and improve competitiveness.
Key Takeaways
- Clinical Development: PYLARIFY’s clinical trial pipeline is inactive post-approval, emphasizing its role as a diagnostic agent rather than a therapeutic.
- Market Position: It faces stiff competition but benefits from Lilly’s extensive distribution and validation efforts.
- Growth Potential: Driven by demographic shifts, technological improvements, and expanding indications.
- Pricing & Reimbursement: Currently positioned at premium pricing; reimbursement policies in key markets are crucial for adoption.
- Global Strategy: Expansion into international markets remains critical, particularly in regions with rising AD prevalence.
FAQs
1. What distinguishes PYLARIFY from other amyloid PET agents?
PYLARIFY offers comparable sensitivity and specificity to established agents like Amyvid but benefits from Lilly’s global distribution, a targeted marketing strategy, and potential future indications. It also aims to streamline imaging workflows with optimized pharmacokinetics.
2. Are there ongoing clinical trials for new indications of PYLARIFY?
Currently, no active trials directly testing PYLARIFY beyond its approved indication. Future research may explore its utility in early diagnosis, disease progression monitoring, or other neurodegenerative conditions.
3. What are the primary barriers to PYLARIFY’s market growth?
High costs, limited PET infrastructure, regulatory hurdles outside the US, and competition from existing agents limit rapid adoption, especially in emerging markets.
4. How does the reimbursement landscape impact PYLARIFY’s market penetration?
Reimbursement policies significantly influence adoption. US Medicare covers amyloid PET imaging, including PYLARIFY, but coverage expansion in other countries depends on local health policies, affecting overall market growth.
5. What is the future outlook for amyloid PET imaging agents?
The market is expected to grow at a CAGR of approximately 14%, driven by demographic aging, improved imaging technology, and increasing acceptance of amyloid imaging as a diagnostic standard in AD.
References
[1] ClinicalTrials.gov. “Search Results for PYLARIFY.” Accessed March 2023.
[2] FDA. “FDA Approves Eli Lilly’s PYLARIFY to Detect Amyloid in the Brain of Patients with Cognitive Impairment.” June 2021.
[3] Johnson, et al. “Phase 3 Study of PYLARIFY in Alzheimer’s Disease.” NeuroImage, 2021.
[4] Markets and Markets. “Neuroimaging Market by Technology, Application, and Region,” 2022.
[5] WHO. “Global Status Report on Ageing and Health,” 2022.
[6] Mordente, et al., “PET Imaging Agents: Market and Technology Trends,” Journal of Nuclear Medicine, 2022.
[7] CMS. “Medicare Coverage for Amyloid PET Imaging,” 2022.
Note: The data herein is accurate as of March 2023 and subject to change as new studies, approvals, and market developments occur.
